Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.75M Sell
6,960
-70
-1% -$15.1K 1% 14
2026
Q1
$1.53M Sell
7,030
-223
-3% -$49.5K 0.87% 16
2025
Q4
$1.66M Sell
7,253
-159
-2% -$36.2K 1.01% 13
2025
Q3
$1.72M Buy
7,412
+24
+0.3% +$4.89K 1.22% 12
2025
Q2
$1.37M Sell
7,388
-19
-0.3% -$3.53K 1.06% 16
2025
Q1
$1.55M Buy
7,407
+108
+1% +$21K 1.21% 14
2024
Q4
$1.3M Buy
7,299
+1
+0% +$184 1.03% 18
2024
Q3
$1.44M Buy
7,298
+404
+6% +$75.4K 1.06% 17
2024
Q2
$1.18M Sell
6,894
-170
-2% -$28.2K 0.93% 21
2024
Q1
$1.29M Buy
7,064
+51
+0.7% +$8.79K 0.97% 20
2023
Q4
$1.09M Buy
7,013
+61
+0.9% +$8.89K 0.87% 23
2023
Q3
$1.04M Sell
6,952
-11
-0.2% -$1.61K 0.85% 29
2023
Q2
$938K Sell
6,963
-326
-4% -$47.8K 0.78% 32
2023
Q1
$1.16M Sell
7,289
-171
-2% -$26.1K 0.97% 21
2022
Q4
$1.21M Sell
7,460
-137
-2% -$21K 1.07% 17
2022
Q3
$1.02M Buy
7,597
+477
+7% +$68.4K 1.09% 17
2022
Q2
$1.09M Buy
7,120
+174
+3% +$26.6K 1.14% 16
2022
Q1
$1.13M Sell
6,946
-1,275
-16% -$185K 1.04% 19
2021
Q4
$1.11M Buy
+8,221
New +$971K 1.09% 19

Other funds holding ABBV

Basepoint Wealth's ABBV Position: Q2 2026 in Review

Basepoint Wealth reduced its AbbVie (ABBV) stake by 1% in Q2 2026, selling an estimated $15.1K and leaving 6,960 shares worth $1.75M. The position accounts for 1% of the portfolio, ranked #14.

Basepoint Wealth first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,218 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Basepoint Wealth held 6,960 shares of AbbVie worth $1.75M as of Q2 2026.
  • Basepoint Wealth sold 70 AbbVie shares in Q2 2026, an estimated $15.1K.
  • AbbVie made up 1% of Basepoint Wealth's portfolio in Q2 2026, its #14 holding.
  • Basepoint Wealth first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 4,218 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Basepoint Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.